These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
467 related articles for article (PubMed ID: 33037986)
21. Nanobodies: a promising approach to treatment of viral diseases. Minatel VM; Prudencio CR; Barraviera B; Ferreira RS Front Immunol; 2023; 14():1303353. PubMed ID: 38322011 [TBL] [Abstract][Full Text] [Related]
22. Research Progress and Applications of Multivalent, Multispecific and Modified Nanobodies for Disease Treatment. Wang J; Kang G; Yuan H; Cao X; Huang H; de Marco A Front Immunol; 2021; 12():838082. PubMed ID: 35116045 [TBL] [Abstract][Full Text] [Related]
23. Characterization and applications of Nanobodies against human procalcitonin selected from a novel naïve Nanobody phage display library. Yan J; Wang P; Zhu M; Li G; Romão E; Xiong S; Wan Y J Nanobiotechnology; 2015 May; 13():33. PubMed ID: 25944262 [TBL] [Abstract][Full Text] [Related]
24. Allosteric Determinants of the SARS-CoV-2 Spike Protein Binding with Nanobodies: Examining Mechanisms of Mutational Escape and Sensitivity of the Omicron Variant. Verkhivker G Int J Mol Sci; 2022 Feb; 23(4):. PubMed ID: 35216287 [TBL] [Abstract][Full Text] [Related]
25. Characterization of camel nanobodies specific for superfolder GFP fusion proteins. Twair A; Al-Okla S; Zarkawi M; Abbady AQ Mol Biol Rep; 2014 Oct; 41(10):6887-98. PubMed ID: 25085037 [TBL] [Abstract][Full Text] [Related]
26. Functionalization of Magnetic Beads with Biotinylated Nanobodies for MALDI-TOF/MS-Based Quantitation of Small Analytes. Lassabe G; Pírez-Schirmer M; González-Sapienza G Methods Mol Biol; 2022; 2446():531-546. PubMed ID: 35157292 [TBL] [Abstract][Full Text] [Related]
28. Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies. Zuo J; Li J; Zhang R; Xu L; Chen H; Jia X; Su Z; Zhao L; Huang X; Xie W BMC Genomics; 2017 Oct; 18(1):797. PubMed ID: 29041922 [TBL] [Abstract][Full Text] [Related]
29. Identification of Useful Nanobodies by Phage Display of Immune Single Domain Libraries Derived from Camelid Heavy Chain Antibodies. Romao E; Morales-Yanez F; Hu Y; Crauwels M; De Pauw P; Hassanzadeh GG; Devoogdt N; Ackaert C; Vincke C; Muyldermans S Curr Pharm Des; 2016; 22(43):6500-6518. PubMed ID: 27669966 [TBL] [Abstract][Full Text] [Related]
30. VHH Nanobody Versatility against Pentameric Ligand-Gated Ion Channels. Nemecz D; Nowak WA; Nemecz Á J Med Chem; 2024 Jun; 67(11):8502-8518. PubMed ID: 38829690 [TBL] [Abstract][Full Text] [Related]
31. Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy. Panikar SS; Banu N; Haramati J; Del Toro-Arreola S; Riera Leal A; Salas P J Control Release; 2021 Jun; 334():389-412. PubMed ID: 33964364 [TBL] [Abstract][Full Text] [Related]
32. Nanobody‑horseradish peroxidase and -EGFP fusions as reagents to detect porcine parvovirus in the immunoassays. Lu Q; Li X; Zhao J; Zhu J; Luo Y; Duan H; Ji P; Wang K; Liu B; Wang X; Fan W; Sun Y; Zhou EM; Zhao Q J Nanobiotechnology; 2020 Jan; 18(1):7. PubMed ID: 31910833 [TBL] [Abstract][Full Text] [Related]
33. The development of nanobodies for therapeutic applications. Van Bockstaele F; Holz JB; Revets H Curr Opin Investig Drugs; 2009 Nov; 10(11):1212-24. PubMed ID: 19876789 [TBL] [Abstract][Full Text] [Related]
34. NanoBERTa-ASP: predicting nanobody paratope based on a pretrained RoBERTa model. Li S; Meng X; Li R; Huang B; Wang X BMC Bioinformatics; 2024 Mar; 25(1):122. PubMed ID: 38515052 [TBL] [Abstract][Full Text] [Related]
35. Fully synthetic platform to rapidly generate tetravalent bispecific nanobody-based immunoglobulins. Misson Mindrebo L; Liu H; Ozorowski G; Tran Q; Woehl J; Khalek I; Smith JM; Barman S; Zhao F; Keating C; Limbo O; Verma M; Liu J; Stanfield RL; Zhu X; Turner HL; Sok D; Huang PS; Burton DR; Ward AB; Wilson IA; Jardine JG Proc Natl Acad Sci U S A; 2023 Jun; 120(24):e2216612120. PubMed ID: 37276407 [TBL] [Abstract][Full Text] [Related]
36. Structural and Computational Studies of the SARS-CoV-2 Spike Protein Binding Mechanisms with Nanobodies: From Structure and Dynamics to Avidity-Driven Nanobody Engineering. Verkhivker G Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328351 [TBL] [Abstract][Full Text] [Related]
37. NANOBODIES®: A Review of Diagnostic and Therapeutic Applications. Jin BK; Odongo S; Radwanska M; Magez S Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36983063 [TBL] [Abstract][Full Text] [Related]
38. Single Domain Antibody application in bacterial infection diagnosis and neutralization. Qin Q; Liu H; He W; Guo Y; Zhang J; She J; Zheng F; Zhang S; Muyldermans S; Wen Y Front Immunol; 2022; 13():1014377. PubMed ID: 36248787 [TBL] [Abstract][Full Text] [Related]
39. Nanobody-based CD38-specific heavy chain antibodies induce killing of multiple myeloma and other hematological malignancies. Schriewer L; Schütze K; Petry K; Hambach J; Fumey W; Koenigsdorf J; Baum N; Menzel S; Rissiek B; Riecken K; Fehse B; Röckendorf JL; Schmid J; Albrecht B; Pinnschmidt H; Ayuk F; Kröger N; Binder M; Schuch G; Hansen T; Haag F; Adam G; Koch-Nolte F; Bannas P Theranostics; 2020; 10(6):2645-2658. PubMed ID: 32194826 [No Abstract] [Full Text] [Related]